IP Library Patent Application 14603932
Patent Application
App. No. 14/603,932

MODULATION OF ZINC LEVELS TO IMPROVE TISSUE PROPERTIES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/603,932
Abstract

Methods of altering properties of tissues, by providing an effective modifying amount of zinc, which may be in the form of zinc ions. This is accomplished through the use of topical compositions containing one or more zinc-containing components such as salts and/or other zinc compounds or complexes, particularly zinc acetate. Altering properties of tissues includes increasing or decreasing fatty tissue, increasing or decreasing epidermal thickness, increasing elastin content, and preventing or treating gum regression or atrophy. Also disclosed is the provision of a contact lens coated with a zinc-containing material, to improve vision by increasing elastin content of the lens of the eye through release of zinc ions.

Claims (18)

1 - 35 . (canceled)

36 . A method for increasing epidermal thickness in a subject comprising topically applying a composition consisting essentially of one or more zinc-containing components in admixture with a dermatologically or pharmaceutically acceptable carrier, in an effective epidermal-thickness-increasing amount, to a site of the skin of the subject in need of increased epidermal thickness.

37 . A method according to claim 36 wherein the composition is topically applied to one or more areas in the face that have fine lines or wrinkles, and/or to other areas of the skin exhibiting epidermal atrophy due to age or due to an underlying pathological state.

38 . A method according to claim 36 wherein the composition comprises one or more zinc compounds.

39 . A method according to claim 36 wherein the composition comprises one or more zinc salts.

40 . A method according to claim 39 wherein the one or more zinc salts is selected from the group consisting of zinc acetate, ascorbate, aspartate, butyrate, caproate, caprylate, carbonate, chromate, citraconate, citramalate, citrate, EDTA, formate, fumarate, gallate, gluconate, halides, iodate, lactate, laurate, laureate, malate, maleate, malonate, metaphosphate, methanesulfonate, monophosphate, myristate, nitrate, octoate, oleate, orotate, orthophosphate, oxalate, oxides, palmitate, permanganate, phenolsulfonate, phosphate, picolinate, propionate, pyrophosphate, salicylate, selenite, stearate, succinate, sulfate, sulfonate, tannate, tartrate, tetrametaphosphate, titanate, transferrin, tripolyphosphate, undecylate, and valerate, and mixtures thereof.

41 . A method according to claim 40 wherein the composition comprises zinc acetate.

42 . A method according to claim 36 wherein the composition comprises one or more zinc chelates.

43 . A method according to claim 36 wherein the composition comprises one or more zinc complexes.

44 . A method according to claim 36 wherein the carrier is a dermatologically acceptable carrier and further comprises a moisturizer.

45 . A method according to claim 36 wherein the one or more zinc-containing component is present in the composition in a concentration of from about 1.0 pM to about 900 μM.

46 . A method according to claim 36 wherein the one or more zinc-containing component is present in the composition in a concentration of from about 100 pM to about 500 μM.

47 - 98 . (canceled)

99 . A method for increasing epidermal thickness a region of skin of a subject that is in need of increased epidermal thickness, the method consisting essentially of applying topically a composition consisting essentially of one or more zinc-containing components in admixture with a dermatologically acceptable carrier to the region of skin of the subject,

wherein the one or more zinc-containing components is selected from the group consisting of zinc acetate, zinc ascorbate, zinc aspartate, zinc butyrate, zinc caproate, zinc caprylate, zinc carbonate, zinc citraconate, zinc citramalate, zinc citrate, zinc EDTA, zinc formate, zinc fumarate, zinc gallate, zinc gluconate, zinc halides, zinc lactate, zinc malate, zinc maleate, zinc malonate, zinc metaphosphate, zinc monophosphate, zinc nitrate, zinc octoate, zinc orotate, zinc orthophosphate, zinc oxalate, zinc phosphate, zinc picolinate, zinc propionate, zinc pyrophosphate, zinc salicylate, zinc selenate, zinc succinate, zinc sulfate, zinc sulfonate, zinc tartrate, zinc tetrametaphosphate, zinc tripolyphosphate, zinc valerate, zinc amino acid complexes, zinc nucleotide complexes, and mixtures thereof,

wherein zinc of the said one or more zinc-containing components is present in the composition at a concentration that increases epidermal thickness without causing irritation due to zinc,

wherein said concentration is in the range of 1.0 pM to 900 μM, and

wherein the epidermal thickness in the region of skin is increased.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY INTEREST Recorded Jul 19, 2017
From: PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0864 →
SECURITY INTEREST Recorded Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
CHANGE OF NAME Recorded May 21, 2015
From: ESSENTIA BIOSYSTEMS, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 035748/0969 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2015
From: REVANCE THERAPEUTICS, INC.
To: PRECISION DERMATOLOGY, INC.
Reel/Frame 035689/0127 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2015
From: CIFRA, PAMELA; DAKE, MICHAEL D.; ELKINS, CHRISTOPHER; WAUGH, JACOB M.
To: ESSENTIA BIOSYSTEMS, INC.
Reel/Frame 035688/0750 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2015
From: DAKE, MICHAEL D.
To: PRECISION DERMATOLOGY, INC.
Reel/Frame 035689/0592 →